Related Experiment Video
Updated: Jun 17, 2026
12:12
Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
Published on: June 16, 2011
Current and Emerging Assays for Measuring Human T-Cell Responses Against Beta-Cell Antigens in Type 1 Diabetes
Ting-Chen Lin1, Matthew Lacorcia1, Stuart I Mannering1
1Immunology and Diabetes Unit, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
Biomolecules
|March 28, 2025
Summary
Measuring T-cell responses in type 1 diabetes (T1D) is challenging. A new assay, BASTA, shows promise for detecting beta-cell antigen-specific CD4+ T-cell responses, aiding T1D diagnosis and therapy evaluation.
Area of Science:
- Immunology
- Endocrinology
- Autoimmune Diseases
Background:
- Type 1 diabetes (T1D) involves T-cell destruction of pancreatic beta cells.
- Current clinical measures of T1D autoimmunity primarily rely on autoantibodies.
- Direct measurement of T-cell responses against beta cells is crucial but difficult.
Purpose of the Study:
- To review challenges in measuring beta-cell antigen-specific T-cell responses in T1D.
- To discuss existing assays for detecting these T-cell responses.
- To introduce and discuss the emerging BASTA assay for human beta-cell antigen-specific CD4+ T-cell responses.
Main Methods:
- Literature review of T-cell response measurement in T1D.
- Analysis of current assay methodologies.
- Discussion of the BASTA assay's potential and application.
Main Results:
- Measuring beta-cell antigen-specific T-cell responses in T1D presents significant challenges.
- Existing assays have limitations in detecting these critical immune responses.
- The BASTA assay offers a promising new method for quantifying human beta-cell antigen-specific CD4+ T-cell responses.
Conclusions:
- Accurate measurement of T-cell responses is vital for T1D understanding and treatment.
- The BASTA assay represents a significant advancement in monitoring T1D-associated T-cell autoimmunity.
- This assay could accelerate T1D diagnosis and the evaluation of immunotherapies.
Related Concept Videos
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...